Lipid-Based Drug Delivery Systems in Myocardial Infarction Treatment

Myocardial infarction (MI) and its associated complications, such as malignant arrhythmias and pathological ventricular remodeling, pose a significant threat to human health. Lipid-based drug delivery systems have emerged as a unique solution due to their excellent biocompatibility, high bioavailability, and ability to carry both hydrophilic and lipophilic compounds. With their broad physicochemical properties that enable tunable biological functions, and the added benefits of straightforward formulation, cost-effective production, and scalability further enhance its potential in targeted therapies. Building on these strengths, Creative Biolabs' lipid-based drug delivery system thus emerges as a highly promising solution, providing precise and efficient drug delivery to the infarcted myocardium and driving advancements in cardiovascular disease treatment.

Background of MI Treatment

Myocardial infarction (MI) is commonly a consequence of the long-term progression of atherosclerosis (As). When atherosclerotic plaques rupture, they release thrombogenic components that activate platelets and trigger the coagulation cascade, leading to thrombus formation and occlusion of distal coronary arteries. This hypercoagulable state can also cause additional plaque ruptures, resulting in multiple lesions, myocardial cell necrosis, fibrosis, and potentially heart failure. Common treatment approaches include pharmacotherapy, antithrombotic therapy, and coronary artery bypass grafting.

Fig.1 Schematic overview of the advances of nanomaterials and applications for both therapeutics and diagnosis.¹

Strategies for Treating MI

The pathological damage in MI primarily involves inflammatory responses and the production of reactive oxygen species (ROS). Therefore, mitigating inflammation, combating ROS damage, and enhancing myocardial tissue repair and regeneration are key strategies for protecting myocardial cells.

• Anti-inflammatory Strategies: The inflammatory microenvironment induces myocardial cell apoptosis and interstitial fibrosis, which are critical pathological mechanisms in MI. Reversing the inflammatory microenvironment in damaged myocardium holds promise for preventing further myocardial cell injury.
• Anti-ROS Strategies: During MI, the production of ROS, including hydrogen peroxide (H₂O₂), superoxide radical anion (O₂⁻), hydroxyl radicals (OH⁻), and singlet oxygen (¹O₂), damages myocardial cell membranes and biomolecules such as proteins and DNA, leading to myocardial cell death and cardiac dysfunction.
• Gene Therapy: Gene-based therapies can counteract cell apoptosis, promote the secretion of endogenous growth factors, and induce angiogenesis, thereby repairing damaged myocardial tissue.
• Myocardial Tissue Repair: Hepatocyte growth factor (HGF) and insulin-like growth factor 1 (IGF-1) enhance the resistance of viable myocardial cells in the infarcted area to injurious factors and induce neovascularization, contributing to myocardial tissue repair.

Lipid-Based Drug Delivery Systems for MI Therapy

Lipid-based drug delivery systems are transforming MI therapy. These advanced systems encapsulate therapeutic molecules within lipid carriers such as liposomes and lipid nanoparticles (LNPs), thereby bypassing biological barriers and achieving direct delivery to affected cardiomyocytes. Creative Biolabs formulates its lipid-based delivery systems with biocompatible and biodegradable lipids, ensuring minimal toxicity and optimal bioavailability. We go beyond standard formulations by offering customized development of functionalized liposomes. Whether you require surface modifications with antibodies, peptides, or other targeting ligands, or need stimuli-responsive release mechanisms, our team of experts is ready to provide one-on-one technical support tailored to your specific needs.

Table 1 Lipid-Based Drug Delivery Systems for MI Therapy

The development of Creative Biolabs' lipid-based delivery system for MI therapy is an ongoing endeavor. Our extensive research and development efforts have focused on optimizing the formulation and targeting mechanisms to achieve maximum therapeutic efficacy. Discover the potential of our lipid-based delivery system for your MI treatment strategies—contact us today.

For Research Use Only. Not For Clinical Use